{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:49:45Z","timestamp":1774702185376,"version":"3.50.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-025-01002-1","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:30:50Z","timestamp":1767000650000},"page":"317-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-1697","authenticated-orcid":false,"given":"Marjolein A. J.","family":"Hiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0648-5043","authenticated-orcid":false,"given":"Anne-Lise","family":"Strandmoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3528","authenticated-orcid":false,"given":"Joost M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"E Schmidt","year":"2019","unstructured":"Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394:882\u201394.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1007\/s00403-002-0366-3","volume":"295","author":"T Hashimoto","year":"2003","unstructured":"Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res. 2003;295(Suppl 1):S2-11.","journal-title":"Arch Dermatol Res"},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","volume":"67","author":"M Amagai","year":"1991","unstructured":"Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869\u201377.","journal-title":"Cell"},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0190-9622(99)70183-0","volume":"40","author":"M Amagai","year":"1999","unstructured":"Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40:167\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-030-91557-5_8","volume-title":"Pemphigus vulgaris, autoimmune bullous diseases: text and review","author":"G Van der Wier","year":"2022","unstructured":"Van der Wier G, Jonkman MF, Horv\u00e1th B. Pemphigus vulgaris, autoimmune bullous diseases: text and review. Berlin: Springer International Publishing AG; 2022. p. 65\u201372."},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66:255\u201370.","journal-title":"Immunol Res"},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12016-024-08980-w","volume":"66","author":"RP Tim\u00f3teo","year":"2024","unstructured":"Tim\u00f3teo RP, Pessoa-Gon\u00e7alves YM, do Carmo Neto JR, Rodrigues WF, da Silva MV, Oliveira CJF. A global view of pemphigus: geographical variations. Clin Rev Allergy Immunol. 2024;66:14\u201329.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","volume":"307","author":"E Alpsoy","year":"2015","unstructured":"Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307:291\u20138.","journal-title":"Arch Dermatol Res"},{"key":"1002_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1326359","volume":"10","author":"F Moro","year":"2023","unstructured":"Moro F, Sinagra JLM, Salemme A, Fania L, Mariotti F, Pira A, et al. Pemphigus: trigger and predisposing factors. Front Med (Lausanne). 2023;10:1326359.","journal-title":"Front Med (Lausanne)"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jaut.2008.08.003","volume":"31","author":"DA Culton","year":"2008","unstructured":"Culton DA, Qian Y, Li N, Rubenstein D, Aoki V, Filhio GH, et al. Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. J Autoimmun. 2008;31:311\u201324.","journal-title":"J Autoimmun"},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0738-081X(83)90028-7","volume":"1","author":"EW Jeffes 3rd","year":"1983","unstructured":"Jeffes EW 3rd, Ahmed AR. Therapy of pemphigus. Clin Dermatol. 1983;1:122\u201340.","journal-title":"Clin Dermatol"},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","volume":"10","author":"D Didona","year":"2019","unstructured":"Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.","journal-title":"Front Immunol"},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41536-025-00426-x","volume":"10","author":"S Rahimi","year":"2025","unstructured":"Rahimi S, Hariton WVJ, Khalaj F, Ludwig RJ, Borradori L, M\u00fcller EJ. Desmoglein-driven dynamic signaling in pemphigus vulgaris: a systematic review of pathogenic pathways. NPJ Regen Med. 2025;10:39.","journal-title":"NPJ Regen Med"},{"key":"1002_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1497241","volume":"15","author":"T Schmitt","year":"2024","unstructured":"Schmitt T, Huber J, Pircher J, Schmidt E, Waschke J. The impact of signaling pathways on the desmosome ultrastructure in pemphigus. Front Immunol. 2024;15:1497241.","journal-title":"Front Immunol"},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","volume":"9","author":"KT Amber","year":"2018","unstructured":"Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;9:1190.","journal-title":"Front Immunol"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncprheum0424","volume":"3","author":"RP Taylor","year":"2007","unstructured":"Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease\u2014the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86\u201395.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","volume":"19","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, D\u00e4hnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. 2010;19:458\u201363.","journal-title":"Exp Dermatol"},{"key":"1002_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1468-3083.2007.02254.x","volume":"21","author":"M Daneshpazhooh","year":"2007","unstructured":"Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, et al. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007;21:1319\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031\u201340.","journal-title":"Lancet"},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/bjd.18482","volume":"182","author":"DM Chen","year":"2020","unstructured":"Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182:1111\u20139.","journal-title":"Br J Dermatol"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","volume":"34","author":"P Joly","year":"2020","unstructured":"Joly P, Horvath B, \u0391 P, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34:1900\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","volume":"156","author":"C Mignard","year":"2020","unstructured":"Mignard C, Maho-Vaillant M, Golinski ML, Balay\u00e9 P, Prost-Squarcioni C, Houivet E, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol. 2020;156:545\u201352.","journal-title":"JAMA Dermatol"},{"key":"1002_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamadermatol.2024.6130","volume":"161","author":"V H\u00e9bert","year":"2025","unstructured":"H\u00e9bert V, Hamwi S, Tancr\u00e8de-Bohin E, Qu\u00e9reux G, Pham-Ledard A, Caux F, et al. Optimizing pemphigus management with rituximab and short-term relapse predictors. JAMA Dermatol. 2025;161:399\u2013405.","journal-title":"JAMA Dermatol"},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","volume":"160","author":"B Tedbirt","year":"2024","unstructured":"Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the Ritux 3 trial. JAMA Dermatol. 2024;160:290\u20136.","journal-title":"JAMA Dermatol"},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamadermatol.2024.6654","volume":"161","author":"B Tedbirt","year":"2025","unstructured":"Tedbirt B, Houivet E, Maho-Vaillant M, Golinski ML, Calbo S, Prost-Squarcioni C, et al. Long-term efficacy and safety of rituximab in patients with pemphigus foliaceus compared with pemphigus vulgaris. JAMA Dermatol. 2025;161:444\u20136.","journal-title":"JAMA Dermatol"},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bjd.18563","volume":"183","author":"V H\u00e9bert","year":"2020","unstructured":"H\u00e9bert V, Vermeulin T, Tanguy L, Tedbirt B, Mignard C, B\u00e9nichou J, et al. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol. 2020;183:121\u20137.","journal-title":"Br J Dermatol"},{"key":"1002_CR27","doi-asserted-by":"crossref","unstructured":"Tedbirt B, De Mulder H, Joly P, Lacroix E, H\u00e9bert V. Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: evaluation from the French healthcare system. J Eur Acad Dermatol Venereol. 2025;39:e524\u2013e5.","DOI":"10.1111\/jdv.20497"},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/1346-8138.17329","volume":"51","author":"SH Shin","year":"2024","unstructured":"Shin SH, Kim JY, Kim SC, Kim JH. Comparative study of efficacy and safety: biosimilar rituximab versus originator rituximab in the treatment of pemphigus. J Dermatol. 2024;51:1104\u20137.","journal-title":"J Dermatol"},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/ced.15213","volume":"47","author":"N Singh","year":"2022","unstructured":"Singh N, Handa S, Mahajan R, Sachdeva N, De D. Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clin Exp Dermatol. 2022;47:1508\u201316.","journal-title":"Clin Exp Dermatol"},{"key":"1002_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/idoj.idoj_534_24","volume":"16","author":"A Kanagarajan","year":"2025","unstructured":"Kanagarajan A, Rai R, Chandrasekaran S, Krishnaswamy M, Sivakumar B. Low dose vs conventional rituximab regimen in pemphigus vulgaris\u2014a retrospective single centre comparative analysis to assess the clinical efficacy and cost-effectiveness. Indian Dermatol Online J. 2025;16:551\u20136.","journal-title":"Indian Dermatol Online J"},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamadermatol.2022.2878","volume":"158","author":"MKY Chen","year":"2022","unstructured":"Chen MKY, Vissapragada R, Bulamu N, Gupta M, Werth V, Sebaratnam DF. Cost-utility analysis of rituximab vs mycophenolate mofetil for the treatment of pemphigus vulgaris. JAMA Dermatol. 2022;158:1013\u201321.","journal-title":"JAMA Dermatol"},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/ijd.IJD_306_20","volume":"66","author":"S Das","year":"2021","unstructured":"Das S, Agarwal K, Singh S, Halder D, Sinha S, De A. A comparative study to evaluate the efficacy and cost of rituximab versus dexamethasone cyclophosphamide pulse in patients of pemphigus vulgaris. Indian J Dermatol. 2021;66:223.","journal-title":"Indian J Dermatol"},{"key":"1002_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ced\/llaf118","volume":"50","author":"P Sharma","year":"2025","unstructured":"Sharma P, Ahuja R, Sharma A, Arava S, Gupta P, Yadav K, et al. Comparison of clinical efficacy and cost-effectiveness of rituximab infusion and intravenous dexamethasone pulse therapy in pemphigus vulgaris: an open prospective randomized controlled pilot study. Clin Exp Dermatol. 2025;50:1766\u201376.","journal-title":"Clin Exp Dermatol"},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/10428194.2024.2439525","volume":"66","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zhang L, Gao S, Yang Y, Zhang Q, Zhang H, et al. Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial. Leuk Lymphoma. 2025;66:680\u201390.","journal-title":"Leuk Lymphoma"},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"2284047","DOI":"10.1080\/16078454.2023.2284047","volume":"28","author":"T Si","year":"2023","unstructured":"Si T, Ma X, Zhu W, Zhou Y. Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis. Hematology. 2023;28:2284047.","journal-title":"Hematology"},{"key":"1002_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-093920","volume":"15","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, Destere A, Cremoni M, Zorzi K, Brglez V, Benito S, et al. Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial. BMJ Open. 2025;15:e093920.","journal-title":"BMJ Open"},{"key":"1002_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","volume":"132","author":"E Schmidt","year":"2009","unstructured":"Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009;132:334\u201341.","journal-title":"Clin Immunol"},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"384","author":"VP Werth","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384:2295\u2013305.","journal-title":"N Engl J Med"},{"key":"1002_CR39","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1056\/NEJMc2111763","volume":"385","author":"ZH Hopkins","year":"2021","unstructured":"Hopkins ZH, Wu BC, Nousari CH. Rituximab versus mycophenolate mofetil in pemphigus vulgaris. N Engl J Med. 2021;385:1055\u20136.","journal-title":"N Engl J Med"},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jdcr.2020.05.034","volume":"6","author":"DM Klufas","year":"2020","unstructured":"Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020;6:734\u20136.","journal-title":"JAAD Case Rep"},{"key":"1002_CR41","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/1346-8138.17108","volume":"51","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xiao Y, Li X, Wang J, Zhou X, Wang Y, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab. J Dermatol. 2024;51:1026\u201330.","journal-title":"J Dermatol"},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1111\/jdv.20245","volume":"39","author":"J Mao","year":"2025","unstructured":"Mao J, Bao S, Chen Y, Zhuang Z, Chen W, Li G, et al. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi-centre cohort study. J Eur Acad Dermatol Venereol. 2025;39:e244\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1002_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19133","volume":"37","author":"E de-la-Rosa-Fern\u00e1ndez","year":"2023","unstructured":"de-la-Rosa-Fern\u00e1ndez E, Loizate-Sarrionandia I, Gonz\u00e1lez-Rodr\u00edguez J, Herrero-Moyano M, Fern\u00e1ndez-de-Misa-Cabrera R, Su\u00e1rez-Hern\u00e1ndez J. Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management. J Eur Acad Dermatol Venereol. 2023;37:e1104-e1106.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1002_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2021.08.005","volume":"16","author":"G Benesh","year":"2021","unstructured":"Benesh G, Andriano TM, Cohen SR. Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Rep. 2021;16:12\u20135.","journal-title":"JAAD Case Rep"},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","volume":"150","author":"CT Ellebrecht","year":"2014","unstructured":"Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150:1331\u20135.","journal-title":"JAMA Dermatol"},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56:1227\u201337.","journal-title":"Rheumatology (Oxford)"},{"key":"1002_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jdcr.2022.07.011","volume":"27","author":"J Freund","year":"2022","unstructured":"Freund J, Trautinger F, Kopetzky G, Prillinger K. Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus. JAAD Case Rep. 2022;27:114\u20136.","journal-title":"JAAD Case Rep"},{"key":"1002_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100813","volume":"46","author":"K Kuriyama","year":"2022","unstructured":"Kuriyama K, Kitamura Y, Tsuji T, Nishikawa R, Nagata H, Ohshiro M, et al. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. Curr Probl Cancer. 2022;46:100813.","journal-title":"Curr Probl Cancer"},{"key":"1002_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103532","volume":"23","author":"M De Bondt","year":"2024","unstructured":"De Bondt M, Renders J, Struyf S, Hellings N. Inhibitors of Bruton\u2019s tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. Autoimmun Rev. 2024;23:103532.","journal-title":"Autoimmun Rev"},{"key":"1002_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.20431","volume":"185","author":"DF Murrell","year":"2021","unstructured":"Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol. 2021;185:745\u201355.","journal-title":"Br J Dermatol"},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2169\/internalmedicine.0578-17","volume":"57","author":"Y Ito","year":"2018","unstructured":"Ito Y, Makita S, Maeshima AM, Hatta S, Suzuki T, Yuda S, et al. Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab. Intern Med. 2018;57:2395\u20138.","journal-title":"Intern Med"},{"key":"1002_CR52","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/ajd.12615","volume":"58","author":"A Lee","year":"2017","unstructured":"Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton\u2019s kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol. 2017;58:e240\u20132.","journal-title":"Australas J Dermatol"},{"key":"1002_CR53","volume":"16","author":"AI Aleissa","year":"2024","unstructured":"Aleissa AI, Alsulaimani HF, Mohamed T. Pemphigus vulgaris treated with ibrutinib: a case report. Cureus. 2024;16:e61317.","journal-title":"Cureus"},{"key":"1002_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100156","volume":"5","author":"PP Naik","year":"2022","unstructured":"Naik PP. Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors. J Transl Autoimmun. 2022;5:100156.","journal-title":"J Transl Autoimmun"},{"key":"1002_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","volume":"103","author":"J Yamagami","year":"2021","unstructured":"Yamagami J, Ujiie H, Aoyama Y, Ishii N, Tateishi C, Ishiko A, et al. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus. J Dermatol Sci. 2021;103:135\u201342.","journal-title":"J Dermatol Sci"},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40257-020-00544-w","volume":"21","author":"EM Altman","year":"2020","unstructured":"Altman EM. Novel therapies for pemphigus vulgaris. Am J Clin Dermatol. 2020;21:765\u201382.","journal-title":"Am J Clin Dermatol"},{"key":"1002_CR57","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","volume":"144","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, et al. Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study. J Invest Dermatol. 2024;144:1762-1771.e1766.","journal-title":"J Invest Dermatol"},{"key":"1002_CR58","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jid.2024.03.014","volume":"144","author":"AS Payne","year":"2024","unstructured":"Payne AS, Manfredo Vieira S. Bruton\u2019s tyrosine kinase inhibition in pemphigus: an embattled frontier. J Invest Dermatol. 2024;144:1667\u201370.","journal-title":"J Invest Dermatol"},{"key":"1002_CR59","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/j.jid.2021.06.035","volume":"141","author":"CA Nelson","year":"2021","unstructured":"Nelson CA, Tomayko MM. Targeting the FcRn: a novel approach to the treatment of pemphigus. J Invest Dermatol. 2021;141:2777\u201380.","journal-title":"J Invest Dermatol"},{"key":"1002_CR60","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","volume":"141","author":"VP Werth","year":"2021","unstructured":"Werth VP, Culton DA, Concha JSS, Graydon JS, Blumberg LJ, Okawa J, et al. Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus. J Invest Dermatol. 2021;141:2858-2865.e2854.","journal-title":"J Invest Dermatol"},{"key":"1002_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Cs\u00f6rg\u0151 Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186:429\u201339.","journal-title":"Br J Dermatol"},{"key":"1002_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095","volume":"13","author":"M Maho-Vaillant","year":"2022","unstructured":"Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13:863095.","journal-title":"Front Immunol"},{"key":"1002_CR63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","volume":"16","author":"D Meyersburg","year":"2012","unstructured":"Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial. 2012;16:311\u201320.","journal-title":"Ther Apher Dial"},{"key":"1002_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.atherosclerosissup.2017.05.044","volume":"30","author":"J Dietze","year":"2017","unstructured":"Dietze J, Hohenstein B, Tselmin S, Julius U, Bornstein SR, Beissert S, et al. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. Atheroscler Suppl. 2017;30:271\u20137.","journal-title":"Atheroscler Suppl"},{"key":"1002_CR65","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","volume":"28","author":"M Kolesnik","year":"2014","unstructured":"Kolesnik M, Becker E, Reinhold D, Ambach A, Heim MU, Gollnick H, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28:771\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1002_CR66","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bjd\/ljad489","volume":"190","author":"N van Beek","year":"2024","unstructured":"van Beek N, Eming R, Reuss A, Zillikens D, S\u00e1rdy M, G\u00fcnther C, et al. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. Br J Dermatol. 2024;190:657\u201367.","journal-title":"Br J Dermatol"},{"key":"1002_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155026","volume":"129","author":"S Tavakolpour","year":"2020","unstructured":"Tavakolpour S, Mahmoudi H, Mirzazadeh A, Balighi K, Darabi-Monadi S, Hatami S, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine. 2020;129:155026.","journal-title":"Cytokine"},{"key":"1002_CR68","doi-asserted-by":"publisher","first-page":"1563286","DOI":"10.3389\/fimmu.2025.1563286","volume":"16","author":"X Lin","year":"2025","unstructured":"Lin X, Li X, Zhai Z, Zhang M. JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2025;16:1563286.","journal-title":"Front Immunol"},{"key":"1002_CR69","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","volume":"38","author":"A Satyam","year":"2009","unstructured":"Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-pemphigus vulgaris. Immunol Invest. 2009;38:498\u2013509.","journal-title":"Immunol Invest"},{"key":"1002_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","volume":"77","author":"S Tavakolpour","year":"2016","unstructured":"Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016;77:189\u201395.","journal-title":"Cytokine"},{"key":"1002_CR71","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","volume":"153","author":"A Jacobi","year":"2005","unstructured":"Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005;153:448\u20139.","journal-title":"Br J Dermatol"},{"key":"1002_CR72","first-page":"940","volume":"8","author":"A Shetty","year":"2009","unstructured":"Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol. 2009;8:940\u20133.","journal-title":"J Drugs Dermatol"},{"key":"1002_CR73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","volume":"56","author":"F Caso","year":"2013","unstructured":"Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, et al. Refractory pemphigus foliaceus and Beh\u00e7et\u2019s disease successfully treated with tocilizumab. Immunol Res. 2013;56:390\u20137.","journal-title":"Immunol Res"},{"key":"1002_CR74","doi-asserted-by":"publisher","first-page":"1465191","DOI":"10.3389\/fimmu.2024.1465191","volume":"15","author":"A Cheever","year":"2024","unstructured":"Cheever A, Kang CC, O\u2019Neill KL, Weber KS. Application of novel CAR technologies to improve treatment of autoimmune disease. Front Immunol. 2024;15:1465191.","journal-title":"Front Immunol"},{"key":"1002_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603237","volume":"11","author":"M Sadeqi Nezhad","year":"2020","unstructured":"Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment? Front Immunol. 2020;11:603237.","journal-title":"Front Immunol"},{"key":"1002_CR76","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179\u201384.","journal-title":"Science"},{"key":"1002_CR77","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130:6317\u201324.","journal-title":"J Clin Invest"},{"key":"1002_CR78","doi-asserted-by":"crossref","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33:2123\u201340.","DOI":"10.1016\/j.ymthe.2025.03.005"},{"key":"1002_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/nano14010067","author":"S Kusumoputro","year":"2023","unstructured":"Kusumoputro S, Au C, Lam KH, Park N, Hyun A, Kusumoputro E, et al. Liver-targeting nanoplatforms for the induction of immune tolerance. Nanomaterials (Basel). 2023. https:\/\/doi.org\/10.3390\/nano14010067.","journal-title":"Nanomaterials (Basel)"},{"key":"1002_CR80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaut.2009.08.006","volume":"34","author":"A Carambia","year":"2010","unstructured":"Carambia A, Herkel J. CD4 T cells in hepatic immune tolerance. J Autoimmun. 2010;34:23\u20138.","journal-title":"J Autoimmun"},{"key":"1002_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","volume":"66","author":"DG Doherty","year":"2016","unstructured":"Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun. 2016;66:60\u201375.","journal-title":"J Autoimmun"},{"key":"1002_CR82","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00281-022-00942-8","volume":"44","author":"C Gottwick","year":"2022","unstructured":"Gottwick C, Carambia A, Herkel J. Harnessing the liver to induce antigen-specific immune tolerance. Semin Immunopathol. 2022;44:475\u201384.","journal-title":"Semin Immunopathol"},{"key":"1002_CR83","doi-asserted-by":"crossref","unstructured":"Didona D, Hudemann C, Garn H, Krzikalla D, Wang SH, Hinterseher J, Volkmann K, Polakova A, Zakrzewicz A, Feldhoff S, Tikkanen R, Digigow R, Pf\u00fctzner W, Santos A, Zimmer CL, Hahmann M, Harnisch S, R\u00f6sch S, Huguenin S, Eming R, Hahn M, Schauer F, Antiga E, Senatore S, Maglie R, T\u00e4ubel J, Ghoreschi K, Meier K, Solimani F, Sticherling M, Sollfrank L, G\u00fcnther C, Steinbrink K, Magnolo N, van Schaick E, Asnaghi V, Zollmann FS, Pohlner J, Hummel J, Sandbrink R, de Min C, Fleischer S, M\u00f6bs C, Hertl M. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigus, Br J Dermatol. 2025.","DOI":"10.1093\/bjd\/ljaf311"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-01002-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:01:50Z","timestamp":1774699310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-01002-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-01002-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"4 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH and AS have no conflicts to declare. BH reports fees from Janssen Cilag (advisory boards, educational grants, consultations, and investigator initiative studies), AbbVie (advisory boards, educational grants, consultations, and investigator initiative studies), Novartis Pharma (advisory boards, consultations, and investigator initiative studies), UCB Pharma (advisory boards and consultations), Leo Pharma (consultations), Solenne B.V. (investigator initiative studies), Celgene (consultations and investigator initiative studies), Akari Therapeutics (consultations and investigator initiative studies), Philips (consultation), Roche (consultation), Regeneron (consultation), Sanofi (consultation), Argenx (advisory boards and consultations), and Argenx (advisory boards and consultations). All contracts were reviewed by the Board of Directors of the UMCG, and all fees were paid to the institution.\u00a0JM reports fees from Argenx (advisory boards and consultations), Sanofi (consultation), and Janssen-Cilag (consultation). All contracts were reviewed by the Board of Directors of the UMCG, and all fees were paid to the institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Data are available upon reasonable request to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Barbara Horv\u00e1th: Conceptualization, lead; data curation, lead; project administration, lead; visualization, supporting; writing\u2014original draft, lead; writing\u2014review and editing, lead. Marjolein Hiel: Conceptualization, equal; visualization, supporting; writing\u2014review and editing, supporting. Anne-Lise Strandmoe: Conceptualization, equal; visualization, lead; writing\u2014review and editing, supporting. Joost Meijer: Conceptualization, equal; writing\u2014review and editing, supporting.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}